glp 1 receptor agonists incretin mimetics Incretins: How we got here, where we're at and what is coming next GLP-1s & Beyond: Understanding Incretin
Description
Staying proactive today may help practices adapt more effectively to tomorrows changing diabetes landscape
At the end of the day, you need to take a hard look at your own personal situation and see if the risk, however small, is something that you are willing to handle
Increasing healthcare expenditures of governments and availability of low-cost generic drugs are supporting the widespread use of incretin mimetics in disease treatment
Bueter, M
JCI Insight 6 , e153732 (2021)
